Trial Profile
Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Cardiovascular disorders; Heart failure; Myocardial infarction; Stroke; Type 2 diabetes mellitus
- Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
- Acronyms DECLARE; DECLARE-TIMI58
- Sponsors AstraZeneca; AstraZeneca AB
- 22 Dec 2023 Results of Pooled Analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61, assessing interaction between body mass index (BMI) and NT-proBNP with respect to heart failure (HF) risk , published in the European Journal of Heart Failure
- 14 Nov 2023 Results of post-hoc analysis assessing the prognostic value of FIB-4 for cardiovascular outcomes and the effects of dapagliflozin, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
- 28 Aug 2023 Results (n=32) assessing if dapagliflozin could exert cardioprotective effects in anthracycline,carfilzomib and trastuzumab-induced cardiotoxicity through the analysis of ejection fraction, global longitudinal strain (GLS) of both left and right ventricle presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology